Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.
Beijing-based Jacobio Pharmaceuticals Co. Ltd. initiated two first-in-human studies in 2018 in China and the US for JAB-3312, and the start-up took its lead asset into Phase IIa just months later.
The Chinese venture is one of three companies developing a molecule inhibiting SHP2, an important mediator of cellular signaling through the RAS/MAP kinase pathway
Jacobio is aiming to be the second company to enter late-stage development in this oncology class
The sector is continuing to show resilience despite financial and market challenges.
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
